Please login to the form below
statins
This page shows the latest statins news and features for those working in and with pharma, biotech and healthcare.
Esperion craters as deaths mar atherosclerosis drug study
disease (ASCVD) who were not able to control their cholesterol levels using statins alone. ... injection to high-risk patients who cannot control cholesterol levels using statins alone.
Latest news
-
Sanofi, Regeneron offer price cut for cholesterol drug Praluent
Praluent (alirocumab) to high-dose statins reduced cardiovascular events and all-cause mortality compared to statins alone.
-
Amgen gets prevention claim for cholesterol drug Repatha
and the risk of coronary revascularisation procedures by 22% over a two year-period when added to statin therapy.
-
The changing face of medical communications over the past 15 years
We used to work on products such as calcium-channel blockers, statins and ACE inhibitors.
-
CETP inhibitor class finally dies as Merck abandons anacetrapib
with placebo in patients at risk for cardiac events already on statin therapy after four years. ... in reducing cardiovascular events when added to statins.
-
US court lifts ban on sales of Sanofi's Praluent
Both products are used to treat patients who cannot meet cholesterol-lowering targets with existing therapy, such as statin drugs, or who have inherited disorders that cause elevated cholesterol. ... statins market has become generic and commoditised.
More from news
Approximately 11 fully matching, plus 216 partially matching documents found.
Latest Intelligence
-
Holding on to hope for Alzheimer’s advances
In terms of BACE, Prof Roberts said: “Although the drug companies would love to have a drug that you could take like statins against hypercholesterolaemia, to give long-term protection against
-
Does safety sell medicines?
Statins - the most widely prescribed medicines on the planet - might not have been the success story they are without high quality pharmacovigilance detecting the risk of rhabdomyolysis and linking it to
-
Delivering accessible healthcare
Examples of how OTC can help tackle these pressures include the greater availability of statins in some countries and treatments for sexually transmitted diseases that do not require a prescription.
-
Shionogi: an expanding commercial focus
Perhaps best known for being the company that discovered the blockbuster statin Crestor (rosuvostatin), Shionogi has largely restricted its global focus to R&D.
-
Country report: The healthcare market in Germany
In 1996 new on-patent medicines became exempt unless they were part of classes such as statins to control the impact on spending on 'me-too' drugs.
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
How do you define a biotech company?
benefit (eg: statins, PD-1s or TNFs).
-
The changing face of medical communications over the past 15 years
We used to work on products such as calcium-channel blockers, statins and ACE inhibitors.
-
The Missing Ingredient in Online Healthcare: Trust
topics, they may see a recommendation to check out an interactive quiz featuring key points of a statin’ s label.
-
The Missing Ingredient in Online Healthcare: Trust
topics, they may see a recommendation to check out an interactive quiz featuring key points of a statin’ s label.
-
Synergy Vision wins PharmaTimes Media International Communication Agency Team Award 2014
launched statin.
More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.
Featured jobs
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
-
Senior Medical Writer
-
Salary is DOE
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
- Account Director or Senior Account Director
-
Salary TBC
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Account Manager
-
Negotiable
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
Subscribe to our email news alerts
- Moving annual total (MAT)
- AZ prepares to file COPD triple, taking on rival GSK
- J&J files ‘breakthrough’ bladder cancer drug in US
- Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma
- Teva wins FDA OK for crucial migraine drug
- NHS wins legal fight with pharma over off-label Avastin
- IPA’s new training course, Silver Buck launched and ARK moves office
- NHS wins legal fight with pharma over off-label Avastin
- Gilead and ViiV among winners at PM Society Digital Awards
- The critical role of science in healthcare communications
- UK pharma to work with innovation network on NHS uptake
- Bayer roll-out of haemophilia drug Jivi gathers pace
PMHub
M&F Health
M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
